KR101910013B1 - A composition for improving, preventing and treating of pain comprising herb extract - Google Patents
A composition for improving, preventing and treating of pain comprising herb extract Download PDFInfo
- Publication number
- KR101910013B1 KR101910013B1 KR1020170120232A KR20170120232A KR101910013B1 KR 101910013 B1 KR101910013 B1 KR 101910013B1 KR 1020170120232 A KR1020170120232 A KR 1020170120232A KR 20170120232 A KR20170120232 A KR 20170120232A KR 101910013 B1 KR101910013 B1 KR 101910013B1
- Authority
- KR
- South Korea
- Prior art keywords
- pain
- extract
- licorice
- preventing
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 208000002193 Pain Diseases 0.000 title claims abstract description 55
- 230000036407 pain Effects 0.000 title claims abstract description 50
- 235000013305 food Nutrition 0.000 claims abstract description 19
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 claims abstract description 7
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 claims abstract description 7
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 claims abstract description 7
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 claims abstract description 7
- 229960003147 reserpine Drugs 0.000 claims abstract description 7
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 56
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 46
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 46
- 229940010454 licorice Drugs 0.000 claims description 46
- 239000003205 fragrance Substances 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000012676 herbal extract Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 208000001640 Fibromyalgia Diseases 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002304 perfume Substances 0.000 claims description 5
- 239000000052 vinegar Substances 0.000 claims description 4
- 235000021419 vinegar Nutrition 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 241000202807 Glycyrrhiza Species 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 abstract description 20
- 244000075634 Cyperus rotundus Species 0.000 abstract description 2
- 235000016854 Cyperus rotundus Nutrition 0.000 abstract description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract description 2
- 244000116484 Inula helenium Species 0.000 abstract description 2
- 235000002598 Inula helenium Nutrition 0.000 abstract description 2
- 241000146029 Lindera aggregata Species 0.000 abstract description 2
- 244000274050 Platycodon grandiflorum Species 0.000 abstract description 2
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 abstract 1
- 235000016646 Citrus taiwanica Nutrition 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 53
- 230000000052 comparative effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 240000006394 Sorghum bicolor Species 0.000 description 11
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 11
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 235000013376 functional food Nutrition 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 208000004454 Hyperalgesia Diseases 0.000 description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 240000004371 Panax ginseng Species 0.000 description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000008434 ginseng Nutrition 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010053552 allodynia Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000011477 liquorice Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 208000000094 Chronic Pain Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 235000017443 Hedysarum boreale Nutrition 0.000 description 4
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 244000294411 Mirabilis expansa Species 0.000 description 3
- 235000015429 Mirabilis expansa Nutrition 0.000 description 3
- 208000027520 Somatoform disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000013536 miso Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 208000027753 pain disease Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RTBLDXVIGWSICW-JMSVASOKSA-N (1R,7R,10R)-4,10,11,11-tetramethyltricyclo[5.3.1.01,5]undec-4-ene Chemical compound C[C@@H]1CC[C@@H]2CC3=C(C)CC[C@]13C2(C)C RTBLDXVIGWSICW-JMSVASOKSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 244000236655 Diospyros kaki Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- 244000272264 Saussurea lappa Species 0.000 description 2
- 235000006784 Saussurea lappa Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 229940069445 licorice extract Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- BZQURGSQMBBPRU-DZGCQCFKSA-N (4as,8as)-3,8a-dimethyl-5-methylidene-4,4a,6,9-tetrahydrobenzo[f][1]benzofuran Chemical compound C([C@]1(C)C2)=CCC(=C)[C@@H]1CC1=C2OC=C1C BZQURGSQMBBPRU-DZGCQCFKSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000473391 Archosargus rhomboidalis Species 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- APWLDLGOYJHNIK-YUELXQCFSA-N Cyperol Chemical compound C1C[C@@H](O)C(C)=C2C[C@H](C(=C)C)CC[C@]21C APWLDLGOYJHNIK-YUELXQCFSA-N 0.000 description 1
- APWLDLGOYJHNIK-CFVMTHIKSA-N Cyperol Natural products O[C@H]1C(C)=C2[C@](C)(CC1)CC[C@H](C(=C)C)C2 APWLDLGOYJHNIK-CFVMTHIKSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000002714 Extracts of rosemary Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000546273 Lindera <angiosperm> Species 0.000 description 1
- BZQURGSQMBBPRU-ZFWWWQNUSA-N Lindestrene Natural products C=C1[C@H]2[C@@](C)(C=CC1)Cc1occ(C)c1C2 BZQURGSQMBBPRU-ZFWWWQNUSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- MEGPURSNXMUDAE-UHFFFAOYSA-N Scopoline Natural products C1C(O2)CC3N(C)C1C2C3O MEGPURSNXMUDAE-UHFFFAOYSA-N 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019306 extracts of rosemary Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N gamma-hexachlorocyclohexane Natural products ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229960002809 lindane Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- MEGPURSNXMUDAE-RLMOJYMMSA-N scopoline Chemical compound C([C@H](O1)C2)[C@@H]3N(C)[C@H]2[C@H]1[C@H]3O MEGPURSNXMUDAE-RLMOJYMMSA-N 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 향부자, 오약, 목향, 감초, 길경 및 지각으로 이루어진 혼합 추출물(SOCG라고 함)을 유효성분으로 함유하는 통증의 개선, 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for improving, preventing or treating pain comprising as an active ingredient a mixed extract (referred to as SOCG) consisting of a perfume, a fragrance, a moss, a licorice, a longitude and a crust.
통증에는 다양한 분류가 있지만, 기간이나 성질에 따라 생체 경고계의 역할을 하는 급성 통증, 질환이 통상 치유되는 데 필요한 기간을 넘었음에도 불구하고 계속 통증을 호소하는 만성 통증으로 나누어진다. There are various categories of pain, but they are divided into acute pain, which acts as a biological warning system depending on the period or nature, and chronic pain, which continues to be painful even though the period of time required for normal healing is exceeded.
원인에 따라서는 침해 수용성 통증, 신경 장애성 통증, 심인성 통증의 크게 세 가지로 나누어진다. 섬유근 통증은 전신의 참기 어려운 만성 동통을 핵심 증상으로 해서, 불면, 전신 피로감 등 다양한 수반 증상을 수반하는 만성 통증 질환이다. 섬유근 통증의 증상은 매우 다채롭다. Depending on the cause, there are three broad categories: invasive pain, neuropathic pain, and psychogenic pain. The fibromyalgia is a chronic pain disorder with various symptoms including insomnia, general fatigue, and the like, which are the main symptom of chronic pain that is difficult to tolerate by the whole body. Symptoms of fibromyalgia are very diverse.
상기 섬유근 통증의 증상으로는, 근조직 등의 심부 조직의 만성 통증 및 지압시의 통증을 수반하는 것이 특징이다. 또한, 접촉 이질통이나 냉각 이질통과 같은 이질통, 열성 통각 과민을 수반하는 경우도 많다. Symptoms of fibrogenic pain include chronic pain of deep tissues such as muscle tissue and pain accompanied by acupressure. In addition, there are many cases of allodynia such as contact allodynia and cold allodynia, and thermal hyperalgesia.
통증 질환에서는 통증의 원인의 기질적 장애 또는 기능적 장애가 어느 정도 명확한 데 반해, 섬유근 통증 환자는 통증을 설명하는 원인이 명확하지 않다. 섬유근 통증의 진단 기준은 미국 류마티스 학회(the American College of Rheumatology)에 의해, 신체의 광범위하게 미치는 통증이 3개월 이상 지속되는 경우, 및 전신에 있는 (뼈에 접하는 인대, 건, 근육 등) 18곳의 압통점 중 11곳 이상에서 압통이 나타나는 경우로 정해져 있다. In pain disorders, the cause of pain is not clear, while the physical or functional impairment of the cause of pain is somewhat clear. The criteria for the diagnosis of fibromyalgia are defined by the American College of Rheumatology as a result of extensive physical pain of the body lasting more than 3 months and the presence of systemic (ligaments, tendons, muscles, etc.) And the tenderness appears at eleven or more of the tender points of the place.
이 진단 기준은 다른 통증 질환의 진단 기준과는 명확히 다르다. 즉, 섬유근 통증은 증상, 통증의 원인, 진단 기준 등의 관점에서, 다른 통증 질환과는 명확히 다른, 독립적으로 존재하는 만성 질환이다.This diagnostic criterion is clearly different from the diagnostic criteria for other pain disorders. In other words, fibromyalgia is an independent chronic disease that is distinct from other pain disorders in terms of symptoms, causes of pain, and criteria for diagnosis.
최근에, 프레가발린, SNRI(세로토닌·노르아드레날린 재취득 저해제)인 둘록세틴, 도파민 작동약인 프라미펙솔 등의 약제가 섬유근 통증 환자의 증상 스코어를 프라세보군과 비교하여 통계학적으로 유의하게 경감시키는 것으로 보고되었지만, 이들 약제의 효과는 한정적이다. Recently, drugs such as pregabalin, duloxetine, a SNRI (serotonin nor noradrenaline re-uptake inhibitor) and pramipexole, a dopamine agonist, were statistically significant , But the efficacy of these agents is limited.
지금도 섬유근 통증에 대한 안전하고 유효한 치료법은 확립되어 있지 않아, 효과가 충분하면서도 부작용이 적은 새로운 우수한 치료약의 개발이 강하게 요구되고 있다.Even now, safe and effective treatments for fibromyalgia have not yet been established, and there is a strong demand for the development of new excellent therapeutic agents with sufficient effects and fewer side effects.
본 발명의 목적은 향부자, 오약, 목향, 감초, 길경 및 지각으로 이루어진 혼합 추출물(SOCG라고 함)을 유효성분으로 함유하는 통증의 예방 또는 치료용 약학 조성물을 제공하는데 있다.It is an object of the present invention to provide a pharmaceutical composition for preventing or treating pain comprising as an active ingredient, a mixed extract (called SOCG) consisting of root extract, fragrance, sorghum, licorice,
또한, 본 발명의 다른 목적은 향부자, 오약, 목향, 감초, 길경 및 지각으로 이루어진 혼합 추출물(SOCG라고 함)을 유효성분으로 함유하는 통증의 예방 또는 개선용 식품 조성물을 제공하는데 있다.Another object of the present invention is to provide a food composition for preventing or ameliorating pain comprising as an active ingredient, a mixed extract (called SOCG) consisting of a herbal extract, a fragrant extract, a licorice extract, a licorice extract,
상기한 목적을 달성하기 위한 본 발명의 통증 예방 또는 치료용 약학 조성물은 향부자, 오약, 목향, 감초, 길경 및 지각으로 이루어진 혼합 추출물을 유효성분으로 함유할 수 있다.In order to accomplish the above object, the pharmaceutical composition for preventing or treating pain according to the present invention may contain, as an active ingredient, a mixed extract comprising a herbal composition, a fragrance, a herb, a licorice, a ginseng, and a crust.
상기 향부자, 오약, 목향, 감초, 길경 및 지각은 1 : 0.2-0.8 : 0.05-0.3 : 0.05-0.3 : 0.2-0.8 : 0.2-0.8의 중량비로 혼합될 수 있으며, 바람직하게는 1 : 0.4-0.6 : 0.05-0.15 : 0.05-0.15 : 0.4-0.6 : 0.4-0.6의 중량비로 혼합될 수 있다.The perfume, the scent, the seedlings, the licorice root, the root length, and the crust are mixed in a weight ratio of 1: 0.2-0.8: 0.05-0.3: 0.05-0.3: 0.2-0.8: 0.2-0.8, : 0.05-0.15: 0.05-0.15: 0.4-0.6: 0.4-0.6.
상기 혼합 추출물은 물, 탄소수 1 내지 4의 저급알코올, 에틸렌글리콜, 에틸에테르 또는 이들의 혼합용매로 추출된 것일 수 있다.The mixed extract may be extracted with water, a lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof.
상기 통증은 레세르핀(reserpine)의 투여로 인해 유발되는 통증일 수 있다.The pain may be pain caused by the administration of reserpine.
상기 통증은 섬유근 통증일 수 있다.The pain may be fibromyalgia.
또한, 상기한 다른 목적을 달성하기 위한 본 발명의 통증 예방 또는 개선용 식품 조성물은 향부자, 오약, 목향, 감초, 길경 및 지각으로 이루어진 혼합 추출물을 유효성분으로 함유하는 것일 수 있다.In another aspect of the present invention, there is provided a food composition for preventing or improving pain comprising as an active ingredient, a mixed extract consisting of a herbal supplement, a fragrance, a herb, a licorice, a ginseng, and a crust.
본 발명의 향부자, 오약, 목향, 감초, 길경 및 지각으로 이루어진 혼합 추출물을 유효성분으로 함유하는 통증을 개선, 예방 또는 치료할 수 있는 조성물은 독성이 없으며, 레세르핀으로부터 유발된 통증에 진통효과가 우수하므로 통증을 개선, 예방 또는 치료시키는 효능이 매우 뛰어나 경쟁력 있는 식품 조성물 및 의약 조성물의 제조에 효과적이다. The composition capable of improving, preventing or treating the pain comprising the mixed extract of the present invention as an active ingredient is not toxic and has an analgesic effect on the pain caused by the reserpine It is highly effective in improving, preventing or treating pain and is therefore effective for manufacturing competitive food compositions and pharmaceutical compositions.
도 1은 물질적 이질통을 측정하는 과정을 보여준 사진이다.FIG. 1 is a photograph showing a process for measuring physical allodynia.
본 발명은 향부자, 오약, 목향, 감초, 길경 및 지각으로 이루어진 혼합 추출물(SOCG라고 함)을 유효성분으로 함유하는 통증의 개선, 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for improving, preventing or treating pain comprising as an active ingredient a mixed extract (referred to as SOCG) consisting of a perfume, a fragrance, a moss, a licorice, a longitude and a crust.
상기 통증은 레세르핀(reserpine)의 투여로 인해 유발되는 통증으로서, 구체적으로는 섬유근 통증일 수 있다.
The pain is pain caused by the administration of reserpine, specifically fibrosis pain.
이하, 본 발명을 상세하게 설명한다. Hereinafter, the present invention will be described in detail.
본 발명의 통증의 개선, 예방 또는 치료용 조성물은 향부자, 오약, 목향, 감초, 길경 및 지각으로 이루어진 혼합 추출물을 유효성분으로 함유한다.The composition for improving, preventing or treating the pain of the present invention contains as an active ingredient a mixed extract consisting of a herbal extract, a fragrance, a moss, a licorice, a longitude and a crust.
상기 향부자(Cyperus rotundu)는 7~8월에 적색 꽃이 피고 꽃이 2줄로 달리며 10월에 열매가 익는다. 한방에서는 괴근을 통경·진통·감기·조경·건위·경풍·하리·지해·신경통·폐결핵·부인병 등에 사용하는데 주요성분은 정유 Cyperene, Cyperol 등이며 약용부위는 근경으로서 주용도는 예로부터 중국, 인도 등지에서 부인병의 선약으로 일컬어져 온 약재로서 월경불순, 산전산후 두통, 통경(通經), 정혈(精血), 신경안정, 체력강화, 만성 위기능 쇠약, 신경성 소화불량, 식욕 감퇴 등에 특효가 있는 것으로 인정되어 왔다. Cyperus rotundu has red flowers in July to August, two rows of flowers, and fruit ripens in October. In the oriental medicine, it is used for the penetration of tuberous root, analgesic, cold, landscape, dryness, tornado, hari, wrinkle, neuralgia, pulmonary tuberculosis and women's diseases. Major components are essential oil Cyperene and Cyperol. Medicinal area is rhizome. Is a medicinal herb that has been said to be a gynecological pre-disposition. It has a special effect on menstrual irregularities, prenatal postpartum headache, menstruation, blood circulation, nervous stability, strengthening of strength, weakness of chronic gastric dysfunction, .
또한, 상기 오약(Lindera aggregate; Lindera syrychnifolia)은 녹나무과의 식물로서, 타원형 혹은 계란 모양 잎이 어긋나게 붙어있고 노란풀색의 작은 꽃이 핀다. 중국 남부(복건, 절강, 강소, 대만)에 자라며, 뿌리에 0.1~0.2% 정유가 있다. 상기 정유에는 린데네톨(린데네놀(린데렌), 린데스트렌, 린데라락톤 등을 비롯한 테르펜화합물이 있어 주로 말린 뿌리를 약용으로 사용한다. 동의보감에서 방향선건위약, 아픔멎이약, 진경약으로 배가 차서 아픈데, 먹은 것이 올라오며 토하는데, 방광이 차서 오줌을 자주 누는데, 중품으로 뇌익혈 및 지각마비, 머리아픔에 쓴다고 기재되어 있다. 또한 오약은 몸의 기(氣)를 순환시키며, 위를 덥혀주며 다뇨증, 소화장애, 설사, 달거리등에 사용한다. Further, the above-mentioned smell ( Lindera aggregate; Lindera syrychnifolia ) is a camphoraceae plant, with oval or egg-shaped leaves staggered, and has a yellow flower. It grows in southern China (Fujian, Zhejiang, Jiangsu, Taiwan) and has 0.1 ~ 0.2% essential oil in roots. The essential oils include terenine compounds such as lindaneol (lindaneol (lindane), lindestrene, linderolactone, etc.), and mainly dried roots are used for medicinal purposes. It is said that the stomach is used for the hyperactivity of the brain, the pericardial paralysis, the headache, and the circulation of the body (气), and the stomach Warming, polyuria, diarrhea, diarrhea, and use in the month.
또한, 상기 목향(Aucklandia lappa Dene)은 뿌리와 뿌리줄기에 있는 정유(1~5%)를 식혀 결정을 얻는데, 이것을 헬레닌이라고 한다. 그리고 이눌린, 프세우도 이눌린, 사포닌, 쓴맛물질, 등이 있습니다. 그밖에 스코플레틴, 움벨리페론 등이 있다. 가슴통증, 이질, 구토에 좋고, 뿌리의 달임액은 가래를 내보내는 작용이 강하며, 항염작용, 항진된 장운동과 분비작용을 억제한다. 정유는 방부작용, 항염작용이 있고, 가래약, 건위약, 이뇨약, 발한약으로 기관지염, 폐결핵 등 여러가지 호흡기 질병에 쓰인다.In addition, the Aucklandia lappa Dene (Aucklandia lappa Dene) is obtained by cooling essential oils (1-5%) in roots and rootstocks, which are called hellenin. And inulin, pseudo-inulin, saponin, bitter substances, and so on. Others include scopoline and umbeliferone. It is good for chest pain, dysentery, vomiting, and the root lunar drip is strong in excretion of phlegm and inhibits anti-inflammatory action, hypertrophic intestinal motility and secretion. Essential oil has side effects and anti-inflammatory action, and it is used for various respiratory diseases such as phlegm, placebo, diuretic, herbal medicine, bronchitis and pulmonary tuberculosis.
또한, 상기 감초(Glycyrrhiza uralensis FISCH.)는 콩과의 다년생 초본으로, 감초는 한방에서 모든 약재와 조화를 이루면서 효능을 증가시킬 뿐만 아니라 완화, 진통약으로 각종 동통 및 급박증상을 완화하는데 내복용 또는 외용으로 사용되고, 그 자체가 독의 중화작용과 같은 약성이 있다. 예를 들면, 감초는 간장을 보호하고 간기능을 원활하게 하여 피로를 조절하는 약효가 있어서, 감초를 복용하면 그 해독작용에 의해 간의 부담이 경감된다. 식물의 뿌리 및 근경에 트리터펜(triterpene)계 사포닌(saponin), 글리시리진(glycyrrhizin)이 함유되어 있어 약물 중독, 음식물 중독, 체내대사물의 중독뿐만 아니라, 세균독소에 대한 모든 해독작용을 가지며, 항이뇨작용 및 갑상선피지호르몬양의 조절 작용이 있다. 감초는 항염증과 항알레르기 반응작용을 보이며, 아세틸콜린에 대해 길항하는 작용을 나타내며, 아드레날린의 강심작용을 증강시키는 효과가 있다The licorice (Glycyrrhiza uralensis FISCH.) Is a perennial herb of soybean, and licorice is harmonized with all the medicines in herbal medicine and not only increases the efficacy, but also alleviates various pain and urgency symptoms through relaxation and analgesic medication. It is used for external use, and itself has a weakness such as a neutralizing action of the poison. For example, licorice has a medicinal effect to control fatigue by protecting the liver and facilitating liver function, and when the licorice is taken, the burden of liver is reduced by its detoxifying action. It has all the detoxification action against bacterial toxins as well as drug poisoning, food poisoning, metabolism, poisoning by containing triterpene saponin and glycyrrhizin in root and root of plant, Action and regulating the amount of thyroid sebum hormone. Licorice exhibits anti-inflammatory and anti-allergic effects, acts antagonistic to acetylcholine, and has the effect of enhancing the adrenaline action of adrenaline
또한, 상기 길경은 초롱꽃과(Campanulaceae)의 식물인 도라지(Platycodon grandiflorum A. DC.)의 뿌리로서, 주로 거담, 진해작용, 기침 및 기관지염의 치료제로 사용되어 왔으며, NF-kB와 NO 에세이를 통해 항염증 효과, 항암효과, 통증완화효과, 소화효소분비 억제효과, 콜레스테롤 대사 개선효과가 있는 것으로 밝혀졌다.In addition, Gil Kyung is a root of Platycodon grandiflorum A. DC, which is a plant of Campanulaceae. It has been mainly used for the treatment of geomorphic, sea bream, cough and bronchitis. Through NF-kB and NO essay Anti-inflammatory effect, anti-cancer effect, pain relieving effect, suppression of digestive enzyme secretion, and improvement of cholesterol metabolism.
또한, 상기 지각(枳殼)은 산등 Citrus aurantum.(운향과 Rutacceae)의 미성숙한 과실을 건조한 것으로 성미는 싸늘하고 무독하며 맛은 쓰고 맵다. 지각은 폐비 대장경으로 효능과 주치는 위장, 자궁의 평활근의 흥분을 증강시키고 아울러 위장연동을 규칙화한다.In addition, the crust is dried to the immature fruit of citrus aurantum. (Rice and Rutacceae), and the taste is cold and nasty, and the taste is spicy. The crust increases the excitability of gastrointestinal and uterine smooth muscle, and also regulates the gastrointestinal interactions.
상기 향부자, 오약, 목향, 감초, 길경 및 지각은 1 : 0.2-0.8 : 0.05-0.3 : 0.05-0.3 : 0.2-0.8 : 0.2-0.8의 중량비, 바람직하게는 1 : 0.4-0.6 : 0.06-0.2 : 0.06-0.2 : 0.4-0.6 : 0.4-0.6의 중량비, 더욱 바람직하게는 1 : 0.45-0.55 : 0.1-0.15 : 0.1-0.15 : 0.45-0.55 : 0.45-0.55의 중량비로 혼합된다.The weight ratio of the fragrance, the fragrance, the horseradish, the licorice, the root length and the crust is 1: 0.2-0.8: 0.05-0.3: 0.05-0.3: 0.2-0.8: 0.2-0.8, preferably 1: 0.4-0.6: 0.06-0.2: Preferably in a weight ratio of 0.06-0.2: 0.4-0.6: 0.4-0.6, more preferably in a weight ratio of 1: 0.45-0.55: 0.1-0.15: 0.1-0.15: 0.45-0.55: 0.45-0.55.
향부자를 기준으로 오약, 목향, 감초, 길경 및 지각의 함량이 상기 하한치 미만인 경우에는 통증을 개선, 예방 또는 치료하는 효과가 각 한약재를 단독으로 사용하는 경우보다도 낮을 수 있으며, 상기 상한치 초과인 경우에는 통증을 개선, 예방 또는 치료하는 효과가 저하될 수 있다.In the case where the contents of omega, sorghum, licorice, licorice, perianth and crust are less than the lower limit based on the herbal supplement, the effect of improving, preventing or treating pain may be lower than that of each medicinal herb alone, The effect of improving, preventing or treating pain may be reduced.
상기 향부자, 오약, 목향, 감초, 길경 및 지각을 단독으로 사용하는 경우에는 향부자, 오약, 목향, 감초, 길경 및 지각을 함께 사용하는 경우에 비하여 1.5 내지 20배로 낮은 효능을 보인다.In case of using only the herbal supplement, omega, sorghum, licorice root, gill root, and crust, the efficacy is 1.5 to 20 times lower than that of herbal supplement, omega, sorghum, licorice root,
상기 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합물은 추출용매와 1 : 5 내지 25, 바람직하게는 1 : 8 내지 15의 중량비로 혼합하여 90 내지 110 에서 추출하여 추출물을 제조한다. 상기 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합물과 추출용매의 중량비가 상기 범위를 벗어나는 경우에는 추출물에 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합물의 유효성분이 적은 양으로 추출될 수 있다.The mixture of the herbal extract, the ocher, the moss, the licorice, the gill, and the crust is mixed with the extraction solvent at a weight ratio of 1: 5 to 25, preferably 1: 8 to 15, and extracted at 90 to 110 to prepare an extract. When the weight ratio of the mixture of the herbal supplement, the ocher, the mixture of liquorice, liquorice, ginseng, and crust is out of the above range, the active ingredient of the mixture of the herbal supplement, the oyster, the liquorice, the licorice, have.
상기 각 추출물을 추출하는 추출용매는 물, 탄소수 1 내지 4의 저급알코올, 에틸렌글리콜, 에틸에테르 또는 이들의 혼합용매이다. 상기 추출용매로는 특별히 한정하는 것은 아니지만 물로 추출된 추출물이 통증의 개선, 예방 또는 치료에 바람직하게 작용한다.The extraction solvent for extracting each of the above extracts is water, a lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof. The extraction solvent is not particularly limited, but an extract extracted with water is preferably used for improving, preventing or treating pain.
본 명세서에서 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합물을 언급하면서 사용되는 용어 추출물은 추출용매를 처리하여 얻은 조추출물뿐만 아니라 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물의 가공물도 포함한다. 예를 들어, 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.In this specification, the term extract used in reference to a mixture of fragrance, fragrance, vinegar, licorice, licorice, persimmon and crust is not limited to crude extract obtained by treating an extracting solvent, . For example, mixed extracts of herbal extracts, fragrances, sorghum, licorice, longgrass and crust can be prepared in powder form by additional processes such as vacuum distillation and freeze drying or spray drying.
또한, 본 발명의 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물은 광의로는 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합물을 동물에게 투여할 수 있도록 제형화된 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 가공물, 예컨대, 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 분말도 포함하는 의미를 갖는다. 비록 본 발명에서 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합물로 실험을 진행하긴 하였으나, 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 가공물과 같은 형태로도 목적하는 효과를 달성할 수 있음은 당업자라면 예상가능할 것이다.In addition, the mixed extract of fragrant, ocher, sorghum, licorice, longitude, and crust of the present invention can be broadly divided into fragrant fractions, fragrance fragrances, fragrance fragrances, Gypsum, licorice, longitude, and crust, such as a mixed powder of a herbal extract, a mist, a vinegar, a licorice, a long grain, and a crust. Although the present invention has been carried out with a mixture of a perfume, a fragrance, a vinegar, a licorice, a licorice, and a crust, the desired effect can be achieved in the form of a mixture of fragrance, fragrance, Can be expected by one skilled in the art.
한편, 본 명세서에서 용어 '유효성분으로 함유하는'이란 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 일예로, 상기 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물은 10 내지 1500 ㎍/㎖, 바람직하게는 100 내지 1000 ㎍/㎖의 농도로 사용된다. 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물은 천연물로서 과량 투여하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.
As used herein, the term " comprising as an active ingredient " means an amount sufficient to achieve the efficacy or activity of the herbal extract, frail, moss, licorice, For example, the combined extracts of the herbal extract, the scent, the moss, the licorice, the root and the crust are used at a concentration of 10 to 1500 μg / ml, preferably 100 to 1000 μg / ml. Since the mixed extract of the herbal supplement, the miso, the licorice, the licorice, the gill, and the crust is a natural product, there is no adverse effect on the human body even when administered in an excessive amount. Therefore, the quantitative upper limit of the mixed extract of the herbal supplement, May be selected and carried out by a person skilled in the art within a suitable range.
본 발명의 약제학적 조성물은 상기 유효 성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition of the present invention can be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, A lubricant or a flavoring agent can be used.
상기 약제학적 조성물은 투여를 위해서 상기 기재한 유효 성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 약제학적 조성물로 바람직하게 제제화할 수 있다.The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.
상기 약제학적 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 주사 가능한 액제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다.The pharmaceutical composition may be in the form of granules, powders, tablets, coated tablets, capsules, suppositories, liquids, syrups, juices, suspensions, emulsions, drops or injectable solutions. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다.Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile solutions suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
더 나아가 해당분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
본 발명의 약제학적 조성물은 경구 또는 비경구로 투여할 수 있고, 비경구 투여인 경우에는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있으며, 바람직하게는 경구 투여이다.The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, the composition can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration, etc., .
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 약제학적 조성물의 1일 투여량은 0.001-10 g/kg이다.The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate and responsiveness of the patient, Usually, a skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g / kg.
본 발명의 약제학적 조성물은 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention can be prepared in unit dose form by formulating it with a pharmaceutically acceptable carrier and / or excipient or can be manufactured by inserting it into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
또한, 본 발명은 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물을 유효성분으로 함유하는 통증의 개선, 예방 또는 치료용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for improving, preventing or treating pain comprising as an active ingredient, a mixed extract of a herbal supplement, a fragrance, a moss, a licorice, a ginseng, and a crust.
본 발명에 따른 식품 조성물은 상기 약제학적 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 알코올 음료류, 과자류, 다이어트바, 유제품, 육류, 초코렛, 피자, 라면, 기타 면류, 껌류, 아이스크림류, 비타민 복합제, 건강보조식품류 등이 있다.The food composition according to the present invention can be formulated in the same manner as the above pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectioneries, diet bars, dairy products, meat, chocolates, pizza, ram noodles, other noodles, gums, ice cream, .
본 발명의 식품 조성물은 유효성분으로서 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 본 발명의 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종 식물 추출액 등을 추가로 포함시킬 수 있다.The food composition of the present invention may contain, as an active ingredient, components that are commonly added in the manufacture of food, as well as mixed extracts of herbal ingredients, miscellaneous ingredients, herbs, licorice, , Nutrients, flavoring agents, and flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the food composition of the present invention is prepared from a drink and a beverage, it may contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, Various plant extracts, and the like.
본 발명은 상기 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물을 유효성분으로 포함하는 통증의 개선, 예방 또는 치료용 식품 조성물을 포함하는 건강기능식품을 제공한다. 건강기능식품이란, 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. 이와 같은 건강기능식품에 있어서의 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물의 첨가량은, 대상인 건강기능식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량%, 바람직하기로는 0.1 내지 20 중량%의 범위이다. 또한, 환제, 과립제, 정제 또는 캡슐제 형태의 건강기능식품의 경우에는 통상 0.1 내지 100 중량% 바람직하기로는 0.5 내지 80 중량%의 범위에서 첨가하면 된다. 한 구체예에서, 본 발명의 건강기능식품은 환제, 정제, 캡슐제 또는 음료의 형태일 수 있다.The present invention provides a health functional food comprising the food composition for improving, preventing or treating pain comprising the combination extract of the fragrance, the fragrance, the moss, the licorice, the gill, and the crust as an active ingredient. The health functional food is a food prepared by adding a mixed extract of a herbal supplement, a miso, a sorghum, a licorice, a ginseng, and a crust to a food material such as a beverage, a tea, a spice, a gum and a confection or an encapsulation, a powder, This means that it takes a certain effect on health when consumed, but unlike general medicine, there is an advantage that there is no side effect that may occur when a drug is taken for a long time by using food as a raw material. The health functional food of the present invention thus obtained is very useful because it can be ingested routinely. The amount of the mixed extract of the fragrance, the fragrance, the liquorice, the licorice, the ginseng, and the crust of the health functional food can not be uniformly determined depending on the type of the health functional food as a target, , And it is usually in the range of 0.01 to 50% by weight, preferably 0.1 to 20% by weight based on the target food. In the case of health functional foods in the form of pills, granules, tablets or capsules, they may be added usually in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.
또한, 본 발명은 통증의 개선, 예방 또는 치료용 의약 또는 식품의 제조를 위한 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물의 용도를 제공한다. 상기한 바와 같이 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물은 통증의 개선, 예방 또는 치료를 위한 용도로 이용될 수 있다.In addition, the present invention provides the use of herbal extracts, fragrances, sorghum, licorice, ginseng, and crust extracts for the manufacture of medicines or foods for the improvement, prevention or treatment of pain. As described above, the combined extracts of rosemary, fragrance, moss, licorice, rootstock, and crust can be used for improving, preventing or treating pain.
또한, 본 발명은 포유동물에게 유효량의 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물을 투여하는 것을 포함하는 통증의 개선, 예방 또는 치료 방법을 제공한다.The present invention also provides a method of improving, preventing or treating pain comprising administering to a mammal an effective amount of a combined extract of rosemary, myrrh, sorghum, licorice, licorice, longitude and crust.
여기에서 사용된 용어 "포유동물"은 치료, 관찰 또는 실험의 대상인 포유동물을 말하며, 바람직하게는 인간을 말한다.The term "mammal " as used herein refers to a mammal that is the subject of treatment, observation or experimentation, preferably a human.
여기에서 사용된 용어 "유효량"은 연구자, 수의사, 의사 또는 기타 임상의에 의해 생각되는 조직계, 동물 또는 인간에서 생물학적 또는 의학적 반응을 유도하는 유효 성분 또는 약학적 조성물의 양을 의미하는 것으로, 이는 해당 질환 또는 장애의 증상의 완화를 유도하는 양을 포함한다. 본 발명의 유효 성분에 대한 유효량 및 투여횟수는 원하는 효과에 따라 변화될 수 있다. 그러므로, 투여될 최적의 투여량은 당업자에 의해 쉽게 결정될 수 있으며, 질환의 종류, 질환의 중증도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다. 본 발명의 예방, 치료 또는 개선 방법에 있어서, 성인의 경우, 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물을 1일 1회 내지 수회 투여시, 0.001 g/kg 내지 10 g/kg의 용량으로 투여하는 것이 바람직하다.As used herein, the term "effective amount" refers to the amount of active ingredient or pharmaceutical composition that elicits a biological or medical response in a tissue system, animal, or human, as contemplated by a researcher, veterinarian, physician or other clinician, ≪ / RTI > inducing a reduction of the symptoms of the disease or disorder. The effective amount and the administration frequency for the active ingredient of the present invention can be changed according to the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art and will vary with the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, The age, body weight, sex, diet, time of administration, route of administration and fraction of the composition, duration of treatment, concurrent medication, and the like. In the prevention, treatment, or improvement method of the present invention, when an adult is administered once or several times a day with a mixed extract of rosacea, fragrance, sorghum, licorice root, Dose is preferable.
본 발명의 치료방법에서 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물을 유효 성분으로 포함하는 조성물은 경구, 직장, 정맥내, 동맥내, 복강내, 근육내, 흉골내, 경피, 국소, 안구내 또는 피내 경로를 통해 통상적인 방식으로 투여할 수 있다.
In the treatment method of the present invention, the composition comprising the mixed extract of rosemary, fragrance, sorghum, licorice, gill, and crust as an active ingredient can be administered orally, rectally, intravenously, intraarterially, intraperitoneally, intramuscularly, , Intraocularly or intradermally, in a conventional manner.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the present invention. Such variations and modifications are intended to be within the scope of the appended claims.
실시예Example 1. One. 향부자Herbalist :: 오약Broken egg :: 목향elecampane :감초::licorice: 길경Gakyung :지각=1:0.5:0.12:0.12:0.5:0.5의 중량비: Crust = 1: 0.5: 0.12: 0.12: 0.5: 0.5
한국신약 주식회사(Han Kook Shin Yak Pharmaceutical Co., Ltd., Nonsan, Korea)에서 구입한 향부자, 오약, 목향, 감초, 길경 및 지각을 1 : 0.5 : 0.12 : 0.12 : 0.5 : 0.5의 중량비로 혼합한 후 상기 혼합물과 물을 1 : 10의 중량비로 혼합하여 90 에서 3시간 동안 열수 추출함으로써 향부자, 오약, 목향, 감초, 길경 및 지각의 혼합 추출물을 수득하였다.
0.5, 0.1: 0.12: 0.5: 0.5, weight ratio of herbal extract, miso, liquorice, licorice, gill, and crust purchased from Han Kook Shin Yak Pharmaceutical Co., Ltd., Nonsan, Then, the mixture was mixed with water at a weight ratio of 1:10, and the mixture was extracted with hot water at 90 for 3 hours to obtain a combined extract of herbal extract, fragrant, moss, licorice, longitude and crust.
비교예 1. 향부자:오약:목향:감초:길경:지각=1:1.5:0.5:0.5:1.5:1.5의 중량비Comparative Example 1 Weight ratio of fragrance: ocher: corn liquor: licorice: persimmon: crust = 1: 1.5: 0.5: 0.5:
상기 실시예 1과 동일하게 실시하되, 향부자, 오약, 목향, 감초, 길경 및 지각을 1 : 1.5 : 0.5 : 0.5 : 1.5 : 1.5의 중량비로 혼합하여 혼합 추출물을 수득하였다.
The mixture was mixed in the same manner as in Example 1 except that the fragrance, the scent, the liquorice, the licorice, the root, and the crust were mixed at a weight ratio of 1: 1.5: 0.5: 0.5: 1.5: 1.5 to obtain a mixed extract.
<시험예><Test Example>
대조군, 실시예 및 비교예에서 제조된 추출액을 여과한 후 여액을 60 이하에서 감압농축하여 이용하였다.Control, Examples and Comparative Examples The extract was filtered, and the filtrate was concentrated under reduced pressure at 60 or less.
시험예 1. 통증 실험Test Example 1. Pain test
250~300 g의 Wistar 랫트(SAMTAKO, Korea, 숫컷)를 실험에 사용하였다. 아크릴 케이지(45 X 60 X 25 cm)에서 사육되었으며, 충분한 사료와 물이 공급되며 적절한 인공조도로 12시간의 낮, 밤을 조절하였다(am 8:00부터 낮). 그리고 일정한 온도(20~24) 및 습도(45~65%)를 유지시켜 주었다. 바뀐 환경에 적응하도록 일주일간 살펴보며 수면주기를 유지하고, 이상행동을 확인하였다. 250-300 g of Wistar rats (SAMTAKO, Korea, male) were used in the experiment. The animals were housed in an acrylic cage (45 x 60 x 25 cm), fed with sufficient feed and water, and adjusted for 12 hours of daytime and night with appropriate artificial illumination (from 8:00 am). And maintained a constant temperature (20 ~ 24) and humidity (45 ~ 65%). We observed for a week to adjust to the changed environment, maintained the sleep cycle, and confirmed abnormal behavior.
동물을 사용한 모든 실험은 MFDS's(Ministry of Food and Drug Safety) National Institute of Toxicological Research for the care and use of laboratory animals(KHUASP(SE)-14-051)를 준수하고, 대전대 동물실험윤리위원회에서 실험 방법을 승인하였다.All experiments using animals were performed in compliance with the MFDS's National Institute of Toxicological Research for the care and use of laboratory animals (KHUASP (SE) -14-051) .
실험동물은 체중변화가 일정하고 건강한 동물만을 선별하여 임의 배치법에 의해 생리식염수를 투여한 정상군, 레세르핀(reserpine)을 투여한 대조군, 레세르핀(reserpine)을 투여한 군에 실시예 1 및 비교예 1의 추출물을 투여한 시료 투여군으로 나누었으며 실험군마다 5마리씩 사용하였다. Experimental animals were divided into two groups according to which the animals were divided into the normal group in which physiological saline was administered by randomly selecting healthy animals with a constant weight change, the control group in which reserpine was administered, the group in which reserpine was administered, And the sample administered with the extract of Comparative Example 1 were used. Five mice were used per experimental group.
이때 레세르핀(reserpine)은 3일 동안 하루에 한번 일정한 시간에 1 mg/kg씩 주사로 투여하였으며, 실시예 1 및 비교예 1의 추출물은 하기 농도(100, 200, 300 mg/kg)로 식염수에 녹여 100 ul 경구 투여하였다.The extracts of Example 1 and Comparative Example 1 were administered at the following concentrations (100, 200, 300 mg / kg) at a dose of 1 mg / kg once a day for 3 days Dissolved in saline and orally administered at a dose of 100 μl.
-8개 군의 마우스--8 groups of mice -
정상군: 생리식염수 3일 투여 5마리_1 mg/kg/dayNormal group: 3 days of physiological saline 5 mg / kg / day
대조군 1: 레세르핀 3일 투여 5마리_1 mg/kg/dayControl group 1: 3 days of lecerpine 5 mg / kg / day
대조군 2: 레세르핀 3일 투여_1 mg/kg/day + 가바펜틴(gabapentin)_50 mg/kg(복강 투여)Control group 2: lecerpine for 3 days _1 mg / kg / day + gabapentin _50 mg / kg (intraperitoneally)
실시예 1(100): 레세르핀 3일 투여_1 mg/kg/day + 실시예 1의 추출물 100 mg/kgExample 1 (100): Lercerpine for 3 days _1 mg / kg / day + Extract of Example 1 100 mg / kg
실시예 1(200): 레세르핀 3일 투여_1 mg/kg/day + 실시예 1의 추출물 200 mg/kgExample 1 (200): Lercerpine for 3 days _1 mg / kg / day + Extract of Example 1 200 mg / kg
실시예 1(300): 레세르핀 3일 투여_1 mg/kg/day + 실시예 1의 추출물 300 mg/kgExample 1 (300): Lercerpine for 3 days _1 mg / kg / day + Extract of Example 1 300 mg / kg
비교예 1(100): 레세르핀 3일 투여_1 mg/kg/day + 비교예 1의 추출물 100 mg/kgComparative Example 1 (100): Lercerpine for 3 days _1 mg / kg / day + Extract of Comparative Example 1 100 mg / kg
비교예 1(200): 레세르핀 3일 투여_1 mg/kg/day + 비교예 1의 추출물 200 mg/kgComparative Example 1 (200): Lecerpine for 3 days _1 mg / kg / day + Extract of Comparative Example 1 200 mg / kg
비교예 1(300): 레세르핀 3일 투여_1 mg/kg/day + 비교예 1의 추출물 300 mg/kg
Comparative Example 1 (300): Lecerpine for 3 days _1 mg / kg / day + Extract of Comparative Example 1 300 mg / kg
진통효과 측정Analgesic effect measurement
경구투여 30분 후 물리적 이질통(mechanical allodynia) 실험을 실시하였으며, 상기 물리적 이질통은 건강한 상태에서는 통증을 일으키지 않고 단순한 촉각반응만을 일으킬 정도의 약한 자극을 가했을 때 통증을 느끼는 반응을 의미한다(도 1). 동물을 기계적 이질통의 측정을 위해 와이어 플로어(wire floor)가 있는 케이지에 두었다. 회피 역치(withdrawal threshold)는 전자 폰 프레이 필라멘트(von Frey filament)(Somedic AB, Malmo, Sweden)에 의해 동측성 및/또는 대측성 뒷발에서 측정하였다. 5가지 자극의 중앙값이 데이터 포인트를 제공하였다. 상응하는 95% 신뢰도 한계를 갖는 절반-최대 유효량(ED50)은 최대 작용시의 반-대수 회귀 분석에 의해 측정하였다.The physical allodynia test was performed 30 minutes after the oral administration, and the physical allodynia was a painful response when a weak stimulus was applied to cause a simple tactile response without causing pain in a healthy state (Fig. 1) . The animals were placed in a cage with a wire floor for the measurement of mechanical allodynia. The withdrawal threshold was measured in the ipsilateral and / or contralateral hindpaw by von Frey filament (Somedic AB, Malmo, Sweden). The median of the five stimuli provided data points. The half-maximal effective dose (ED50) with a corresponding 95% confidence limit was determined by semi-log regression analysis at maximum activity.
수득된 곡선 아래 면적(MA area under the curve)으로 진통의 정도를 나타내었다. The area under the curve (MA area under the curve) indicates the degree of pain relief.
(통증의 척도)area
(A measure of pain)
위 표 1에 나타낸 바와 같이, 본 발명의 실시예 1에 따라 제조된 추출물은 진통제를 투여한 대조군 2와 유사한 진통효과를 보이는 것을 확인하였습니다. 특히, 실시예 1의 추출물을 200 mg/kg으로 투여한 군이 다른 군에 비하여 대조군 2와 거의 유사한 진통효과를 보였다.As shown in Table 1 above, the extract prepared according to Example 1 of the present invention showed similar analgesic effects as the control 2 administered with the analgesic agent. In particular, the group administered with the extract of Example 1 at 200 mg / kg exhibited a similar analgesic effect to that of the control group 2 as compared with the other groups.
반면, 비교예 1의 추출물은 실시예 1의 추출물에 비하여 진통효과가 미미한 것을 확인하였다.
On the other hand, it was confirmed that the extract of Comparative Example 1 had less analgesic effect than the extract of Example 1.
하기에 본 발명의 분말을 함유하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, formulation examples of the composition containing the powder of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described.
제제예Formulation example 1. One. 산제의Sanje 제조 Produce
실시예 1에서 얻은 추출물 분말 500 mg500 mg of the extract powder obtained in Example 1
유당 100 mgLactose 100 mg
탈크 10 mgTalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.
The above components are mixed and filled in airtight bags to prepare powders.
제제예Formulation example 2. 정제의 제조 2. Preparation of tablets
실시예 1에서 얻은 추출물 분말 300 mg300 mg of the extract powder obtained in Example 1
옥수수전분 100 mgCorn starch 100 mg
유당 100 mgLactose 100 mg
스테아린산 마그네슘 2 mgMagnesium stearate 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
제제예Formulation example 3. 캅셀제의 제조 3. Preparation of capsules
실시예 1에서 얻은 추출물 분말 200 mg200 mg of the extract powder obtained in Example 1
결정성 셀룰로오스 3 mgCrystalline cellulose 3 mg
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.
The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
제제예Formulation example 4. 주사제의 제조 4. Preparation of injections
실시예 1에서 얻은 추출물 분말 600 mg600 mg of the extract powder obtained in Example 1
만니톨 180 mg180 mg mannitol
주사용 멸균 증류수 2974 mgSterile sterilized water for injection 2974 mg
Na2HPO4 ,12H2O 26 mgNa 2 HPO 4 , 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플 당 상기의 성분 함량으로 제조한다.
It is prepared by the above-mentioned component content per ampoule according to the usual injection preparation method.
제제예Formulation example 5. 5. 액제의Liquid 제조 Produce
실시예 1에서 얻은 추출물 분말 4 g4 g of the extract powder obtained in Example 1
이성화당 10 g10 g per isomer
만니톨 5 g5 g mannitol
정제수 적량Purified water quantity
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100g으로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.
Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 g with purified water, To prepare a liquid agent.
제제예Formulation example 6. 과립제의 제조 6. Preparation of granules
실시예 1에서 얻은 추출물 분말 1,000 mg1,000 mg of the extract powder obtained in Example 1
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 Vitamin A Acetate 70
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mg0.15 mg of vitamin B2
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 Vitamin B12 0.2
비타민 C 10 mgVitamin C 10 mg
비오틴 10 Biotin 10
니코틴산아미드 1.7 mgNicotinic acid amide 1.7 mg
엽산 50 Folic Acid 50
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 mg1.75 mg of ferrous sulfate
산화아연 0.82 mg0.82 mg of zinc oxide
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgSecondary calcium phosphate 55 mg
구연산칼륨 90 mgPotassium citrate 90 mg
탄산칼슘 100 mgCalcium carbonate 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 과립제에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 과립제 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.
The composition ratio of the above-mentioned vitamins and minerals is comparatively comparatively mixed with the granules according to the preferred embodiment. However, the blending ratio may be arbitrarily changed, and the above components are mixed according to the ordinary granule preparation method, Can be prepared and used in the manufacture of a health functional food composition according to a conventional method.
제제예Formulation example 7. 기능성 음료의 제조 7. Manufacture of functional beverages
실시예 1에서 얻은 추출물 분말 1,000 mg 1,000 mg of the extract powder obtained in Example 1
구연산 1,000 mgCitric acid 1,000 mg
올리고당 100 g100 g of oligosaccharide
매실농축액 2 gPlum concentrate 2 g
타우린 1 gTaurine 1 g
정제수를 가하여 전체 900 mLPurified water was added to the flask to obtain a total of 900 mL
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 기능성 음료 조성물 제조에 사용한다. The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 L container, It is used in the production of the functional beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170120232A KR101910013B1 (en) | 2017-09-19 | 2017-09-19 | A composition for improving, preventing and treating of pain comprising herb extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170120232A KR101910013B1 (en) | 2017-09-19 | 2017-09-19 | A composition for improving, preventing and treating of pain comprising herb extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101910013B1 true KR101910013B1 (en) | 2018-10-19 |
Family
ID=64102174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170120232A KR101910013B1 (en) | 2017-09-19 | 2017-09-19 | A composition for improving, preventing and treating of pain comprising herb extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101910013B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220049672A (en) | 2020-10-14 | 2022-04-22 | 주식회사 필홀딩스 | Composition including oriental medicine for improvement of muscular pain and process of treating thereof |
| KR20220126321A (en) * | 2021-03-08 | 2022-09-16 | (주)오성내츄럴바이오 | Composition comprising the crude drugs complex for decreation or treating musculoskeletal disorders, Phamacopuncture injection of oriental medicinie containing the same, Injection containing the same, Acupuncturing method of oriental medicine using the same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103800859A (en) * | 2012-11-15 | 2014-05-21 | 吕亚英 | Traditional Chinese medicinal composition for treating stomach cold |
| CN104758554A (en) | 2015-04-26 | 2015-07-08 | 王伟伟 | Traditional Chinese medicine composition for treating headache |
-
2017
- 2017-09-19 KR KR1020170120232A patent/KR101910013B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103800859A (en) * | 2012-11-15 | 2014-05-21 | 吕亚英 | Traditional Chinese medicinal composition for treating stomach cold |
| CN104758554A (en) | 2015-04-26 | 2015-07-08 | 王伟伟 | Traditional Chinese medicine composition for treating headache |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220049672A (en) | 2020-10-14 | 2022-04-22 | 주식회사 필홀딩스 | Composition including oriental medicine for improvement of muscular pain and process of treating thereof |
| KR20220088644A (en) | 2020-10-14 | 2022-06-28 | 주식회사 필홀딩스 | Composition including oriental medicine for improvement of muscular pain and process of treating thereof |
| KR20220126321A (en) * | 2021-03-08 | 2022-09-16 | (주)오성내츄럴바이오 | Composition comprising the crude drugs complex for decreation or treating musculoskeletal disorders, Phamacopuncture injection of oriental medicinie containing the same, Injection containing the same, Acupuncturing method of oriental medicine using the same |
| KR102453914B1 (en) * | 2021-03-08 | 2022-11-07 | (주)오성내츄럴바이오 | Composition comprising the crude drugs complex for decreation or treating musculoskeletal disorders, Phamacopuncture injection of oriental medicinie containing the same, Injection containing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016532446A (en) | Enbu fermented food or beverage composition | |
| CN113349381A (en) | Food composition capable of relieving depression and preparation method thereof | |
| KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
| KR101861784B1 (en) | A composition for improving, preventing and treating pulmonary disease comprising herb extract | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| KR20190033828A (en) | Compositions for preventing, ameliorating or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising herbal extracts | |
| KR102348044B1 (en) | Composition for preventing, improving or treating burn out syndrome | |
| KR20150022177A (en) | Composition comprising solvent fractionated extracts of Zingiber officinale, which are useful for the prevention, improvement and treatment of functional gastrointestinal and motility disorders | |
| KR101808944B1 (en) | Composition for preventing and treating dysmenorrhea and premature labor comprising non-polar solvent subfraction from Zingiber officinale extract | |
| KR20130029284A (en) | Composition of healthy foods for treatment of dementia | |
| KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
| KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
| CN110063977B (en) | Radix codonopsis and sea buckthorn composite electuary and application thereof | |
| KR102045847B1 (en) | Kyung-ok-go having high acceptability and anti-diabetes activity adding the silk of zea mays and pumpkin | |
| KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
| KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
| KR101248378B1 (en) | Pharmaceutical composition for arthritis treatment and prevention | |
| KR20160082958A (en) | Pharmaceutical composition for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient | |
| JP4669077B1 (en) | Autonomic nerve regulator containing asparagus pseudo-leaf as active ingredient | |
| KR20190126565A (en) | A composition for improving, preventing and treating of pain containing oriental medicine herbs oil extract as an active ingredient | |
| KR20200061285A (en) | Food Composition for blood circulation and for Preventing blood vessel disease Comprising Extract of Galangal | |
| KR102202224B1 (en) | A composition for the prevention or treatment of depression comprising herb extract YJ06 | |
| KR102275824B1 (en) | The anti-diabetes composition containing extract mixture and manufaturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |